Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cereblon expression in multiple myeloma: not ready for prime time

17 Jul 2013

Abstract excerpt

One of the major recent advances in the biology of multiple myeloma (MM) is the discovery of Cereblon (CRBN) as a potential target for immunomodulatory drugs (IMiDs) activity (Zhu et al, 2011). The use of lenalidomide and dexamethasone (Len-Dex) as frontline therapy might become one of the future standards of care in the treatment of symptomatic MM. Therefore, identification of a biological test able to predict...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Multiple Myeloma Research and Treatments
Share to Protein Degradation and Inhibitors
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23862718
DOI: 10.1111/bjh.12478

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cereblon expression in multiple myeloma: not ready for prime timePMID 23862718Read ↗

Detection and Quantification of Cereblon Protein and mRNA in Multiple Myeloma Cell Lines and Primary CD138+multiple Myeloma CellsSemantic proximity Read ↗

Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma.Semantic proximity Read ↗

Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myelomaSemantic proximity Read ↗

Expression, mutation, and methylation of cereblon-pathway genes at pre- and post-lenalidomide treatment in multiple myeloma.Semantic proximity Read ↗

High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide.Semantic proximity Read ↗

The clinical significance of cereblon expression in multiple myelomaSemantic proximity Read ↗

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomideSemantic proximity Read ↗

Polymorphisms within beta-catenin encoding gene affect multiple myeloma development and treatment.Semantic proximity Read ↗

Cereblon enhancer methylation and IMiD resistance in multiple myelomaSemantic proximity Read ↗

Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patientsSemantic proximity Read ↗

Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4Semantic proximity Read ↗

ppGalNAc-T13: A New Molecular Marker of Bone Marrow Involvement in NeuroblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.